Arana superhumanises CSL

By Dylan Bushell-Embling
Friday, 06 June, 2008

Arana (ASX: AAH) and CSL (ASX: CSL) have completed their second collaborative research project together, paving the way for CSL to develop new pharmaceuticals.

A lead antibody from the CSL pharmaceutical pipeline was run through Arana's Superhumanisation technology, which converts murine antibodies into a humanised form. It was further optimised for affinity using Arana's EvoGene technology platform.

As well as the one-off payment for completing the research, Arana will also be entitled to royalties if CSL choose to develop one of the modified antibodies for clinical testing.

This is the second time CSL and Arana have collaborated, and the third collaborative project Arana has completed.

Arana's stock price has remained relatively stable despite the announcement.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd